V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017220 | 160013593 | 1.79 | 75 | Palliative (P) | 2016-09-30 | 2016-10-06 | EW EuroEwing 2012 Arm B VDC/IE | N | N | GEMCITABINE | 101402976 |
| 160017222 | 160013594 | 1.73 | 54.9 | Neo-adjuvant (N) | 2018-02-15 | 2018-02-15 | IPM | Y | N | RUCAPARIB | 100311295 |
| 160017226 | 160013595 | 0 | 107.4 | null | 2015-10-04 | 2015-10-06 | EW EuroEwing 2012 Arm B VC | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100643478 |
| 160017227 | 160013596 | 1.22 | 70.2 | Palliative (P) | 2018-07-02 | 2018-07-02 | GEMCITABINE | 02 | N | IVADO | 100296549 |
| 160017234 | 160013597 | 1.57 | 20.1 | 02 | 2019-03-03 | 2019-04-29 | Carboplatin + Vinorelbine IV | 01 | N | IVADO | 101628809 |
| 160017235 | 160013598 | 1.2 | 32.2 | 03 | 2016-10-19 | 2016-10-19 | Doxorubicin + Ifosfamide | 02 | N | CISPLATIN | 100370884 |
| 160017237 | 160013599 | 1.68 | 59.9 | Palliative (P) | 2019-05-30 | 2019-07-16 | EW EuroEwing 2012 Arm B IE | N | N | STS RHABDO RMS 2005 VIN CYCLO | 101592397 |
| 160017238 | 160013600 | 1.8 | 89.8 | 03 | 2020-08-20 | 2020-08-22 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | CYCLOPHOSPHAMIDE | 101691571 |
| 160017239 | 160013601 | 0 | 95.6 | null | 2014-01-29 | 2014-02-09 | Olaratumab | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101452508 |
| 160017242 | 160013602 | 1.75 | 74 | Palliative (P) | 2019-04-28 | 2019-05-25 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 100044961 |
| 160017245 | 160013603 | 1.69 | 59.8 | null | 2019-04-15 | 2019-04-16 | null | 02 | N | NOT MATCHED | 100445502 |
| 160017246 | 160013604 | 1.65 | 73.6 | Palliative (P) | 2017-12-18 | 2017-12-19 | EW EuroEwing 2012 Arm B VC | 02 | N | BLEOMYCIN | 100598433 |
| 160017247 | 160013605 | 1.61 | 89.1 | null | 2020-11-23 | 2020-12-29 | PEMBROLIZUMAB | 02 | null | DARATUMUMAB | 100922074 |
| 160017251 | 160013606 | 0 | 57.2 | null | 2017-12-27 | 2018-01-12 | CAPECITABINE + OXALIPLATIN | null | null | IPILIMUMAB + NIVOLUMAB | 101434073 |
| 160017253 | 160013607 | 1.62 | 0 | Palliative (P) | null | 2020-03-09 | IVA | null | N | STS RHABDO VIT0910 VINC IRINOTECAN | 100091582 |
| 160017255 | 160013608 | 1.6 | 91.5 | null | 2017-05-07 | 2017-05-08 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100161502 |
| 160017257 | 160013609 | 1.65 | 51 | Palliative (P) | 2018-09-26 | 2018-11-29 | Cisplatin + Paclitaxel | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100397247 |
| 160017258 | 160013610 | 0 | 123.15 | null | 2019-07-25 | 2019-07-28 | PEMBROLIZUMAB | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100638043 |
| 160017260 | 160013611 | 1.75 | 92.6 | Palliative (P) | 2020-01-22 | 2020-01-31 | NB HRNBL | 02 | N | CREATE TRIAL | 100969350 |
| 160017273 | 160013612 | null | null | null | 2016-09-07 | 2018-06-07 | STS Rhabdo RMS 2005 Vin Cyclo | null | null | NB HRNBL-1 COJEC IND COURSE C | 100423693 |
| 160017276 | 160013613 | 1.69 | 58.8 | null | 2017-10-09 | 2017-12-04 | Rucaparib | 02 | null | LANREOTIDE | 100469645 |
| 160017277 | 160013614 | 0 | 7.4 | Neo-adjuvant (N) | 2019-10-05 | 2019-10-06 | GEMCITABINE | 02 | N | IFOSFAMIDE | 100030899 |
| 160017278 | 160013615 | 1.79 | 107 | Curative (C) | null | null | VAI (Ifos 3g/m2) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101343203 |
| 160017282 | 160013616 | 1.56 | 64.9 | Curative (C) | 2021-05-08 | 2021-05-08 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | NOT MATCHED | 100736700 |
| 160017286 | 160013617 | 1.23 | 95.3 | Palliative (P) | 2016-10-25 | 2018-03-03 | VINCRISTINE | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100416736 |
| 160017287 | 160013618 | 1.61 | 75.7 | null | 2016-01-19 | 2016-03-11 | ETOP 13-18 BEAT-meso Trial | 02 | null | GEMCITABINE | 101651506 |
| 160017288 | 160013619 | 0 | 73 | null | 2018-12-22 | 2018-12-23 | Enzalutamide | 02 | null | NOT MATCHED | 100003501 |
| 160017289 | 160013620 | 1.81 | 75.1 | Adjuvant (A) | 2020-09-12 | 2020-09-15 | Doxorubicin + Ifosfamide | 02 | N | CYCLOPHOSPHAMIDE | 100226239 |
| 160017290 | 160013621 | 1.46 | 117.8 | null | 2016-11-29 | 2016-11-29 | Doxorubicin + Ifosfamide | 02 | null | CISPLATIN + CYTARABINE | 101351572 |
| 160017291 | 160013622 | 1.56 | 17.8 | null | null | 2020-01-19 | CYCLOPHOSPHAMIDE + VINORELBINE | null | null | OLARATUMAB | 101414212 |
| 160017297 | 160013623 | 0 | 106.6 | Curative (C) | 2019-09-05 | 2019-09-12 | Rucaparib | 02 | N | IFOSFAMIDE | 101018565 |
| 160017298 | 160013624 | 1.67 | 68.1 | Palliative (P) | 2019-02-12 | 2019-02-12 | VINCRISTINE | 02 | N | CISPLATIN + ETOPOSIDE | 101191782 |
| 160017299 | 160013625 | 1.82 | null | null | 2016-11-21 | 2016-11-29 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100029304 |
| 160017311 | 160013626 | 0.93 | 35 | Neo-adjuvant (N) | 2018-12-28 | 2019-08-07 | GEMCITABINE | N | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100104842 |
| 160017314 | 160013627 | 1.73 | 77 | Palliative (P) | 2017-09-01 | 2017-09-01 | VAC | 02 | N | NB BEACON TEMOZOLOMIDE ALONE | 101633755 |
| 160017317 | 160013628 | 1.55 | 67.6 | null | 2018-10-06 | 2020-01-15 | ETOP 13-18 BEAT-meso Trial | N | null | POMALIDOMIDE | 101618593 |
| 160017318 | 160013629 | 1.65 | 100.4 | Palliative (P) | 2018-09-30 | 2019-02-04 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | TEMOZOLOMIDE | 100679489 |
| 160017319 | 160013630 | 1.15 | 111.2 | null | 2017-09-22 | 2017-11-22 | Ifosfamide 3g/m2 5 day | 2 | null | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 100721299 |
| 160017321 | 160013631 | 1.87 | 81 | Palliative (P) | 2015-09-22 | 2016-05-22 | Doxorubicin + Ifosfamide | N | N | GEMCITABINE | 101584698 |
| 160017323 | 160013632 | 1.74 | 114.8 | Curative (C) | 2016-11-11 | 2016-11-21 | MELPHALAN | 02 | N | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 101178515 |
| 160017328 | 160013633 | 1.65 | 54 | Curative (C) | 2020-03-20 | 2020-03-24 | IMATINIB | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101659424 |
| 160017330 | 160013634 | 1.65 | 52.35 | null | 2018-07-30 | 2018-08-14 | Doxorubicin + Ifosfamide | 02 | null | OLAPARIB | 101791368 |
| 160017331 | 160013635 | 1.74 | 94 | Curative (C) | 2019-09-26 | 2019-12-26 | Carboplatin + Liposomal Doxorubicin | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100683540 |
| 160017335 | 160013636 | 1.65 | 59.8 | null | 2018-10-03 | 2019-05-07 | Cyclophosphamide oral | 02 | null | DACARBAZINE | 100789822 |
| 160017337 | 160013637 | 1.8 | 49.3 | Palliative (P) | 2018-03-25 | 2018-12-10 | Trial Unspecified | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100402879 |
| 160017339 | 160013638 | 1.69 | 72.5 | Palliative (P) | 2020-07-08 | 2020-09-03 | GEMCITABINE | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101225579 |
| 160017342 | 160013639 | 1.83 | 57 | null | 2018-10-16 | 2019-01-03 | BUSULFAN + MELPHALAN | 02 | null | IVA | 100659435 |
| 160017353 | 160013640 | 1.59 | 49.3 | null | 2020-01-04 | 2020-02-21 | Trial Unspecified | N | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101144008 |
| 160017354 | 160013641 | null | null | null | 2016-06-05 | 2016-12-09 | PROMISE-MESO TRIAL | 01 | null | ETOP 13-18 BEAT-MESO TRIAL | 101603955 |
| 160017356 | 160013642 | 1.7 | 75.4 | Curative (C) | 2016-04-22 | 2017-01-31 | Melphalan + Treosulfan - HD | 02 | N | NOT MATCHED | 100674741 |